Conclusion and Final Thoughts on Managing Breast Cancer
Published Online: Friday, October 11, 2013
For High-Definition, ClickIn the final segment, moderator, Adam M. Brufsky, MD, PhD, asks each panelist for their final thoughts on the management of metastatic breast cancer. Sara Hurvitz, MD, notes her excitement over the number of therapeutic options available to treat patients with HER2 and ER-positive breast cancer, particularly since many of these treatments have less toxicity.
The depth of understanding of tumor microenvironments and biology in breast cancer is due to a global collaboration among researchers, states Edith A. Perez, MD. Additionally, she believes, panel discussions, like this one, help to translate research into clinical practice.
Significant advances have been made in recent years in the treatment of patients with ER-positive disease, believes Hope S. Rugo, MD. Additionally, the therapies developed to treat metastatic disease are beginning to transition into the early-stage setting, representing a significant increase in the number of neoadjuvant treatments. Furthermore, Rugo adds, there is now a better understanding of the subtypes of ER-positive and overcoming resistance, which has improved outcomes for patients.
The level of competition in this space has resulted in the rapid development of novel treatments, says Joyce A. O'Shaughnessy, MD. Therapies have advanced from phase I trials quickly into phase III. In the end, this rapid development greatly benefits patients with this disease.
The treatment of breast cancer is at a tipping point, now that the biology of intrinsic subtypes has been revealed, states Andrew D. Seidman, MD. The level of molecular knowledge allows for the rational development of targeted therapeutics and combinations that avoid feedback looks that overcome therapeutic efficacy, Seidman states. Echoing this, Brufsky notes this is the beginning of the genomic era of our understanding of breast cancer, which may have implications for clinical trial design.
View More From This Discussion
Sara Hurvitz, MDAssistant Professor & Director,
Hematology/Oncology Breast Cancer Program, UCLA's Jonsson Comprehensive Cancer Center, Los Angeles, California
Joyce A. O’Shaughnessy, MDCo-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology, PA/US Oncology,
Edith A. Perez, MDDeputy Director of the Mayo Clinic Cancer Center, Director of the Breast Cancer Translational Genomics Program and the Breast Program at Mayo Clinic,
Hope S. Rugo, MDProfessor of Medicine and Director of the Breast Oncology, Clinical Trials, and Education Program, University of California San Francisco Comprehensive Cancer Center, San Francisco, California
Andrew D. Seidman, MDProfessor of Medicine, Weill Cornell Cancer Center, Attending Physician at Memorial Sloan Kettering Cancer Center,
New York, New York
Online CME Activities
Most Popular Right Now
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.